This ADC product is composed of an anti-ENPP3 antibody conjugated via mc linker to MMAF (anti-ENPP3-mc-MMAF). It is in phase I clinical trials and has demonstrated a response in renal cell carcinoma treatment by a MOA (Mechanism of Action) of microtubules depolymerizing.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
MOB-2302z | Mouse Anti-ENPP3 Recombinant Antibody (clone 5C1) | WB, ELISA, IP | Mouse IgG2a, κ |
MOB-0665CT | Recombinant Mouse anti-Human ENPP3 Monoclonal antibody (OQ5E7) | FC, ICC/IF | |
VS4-WK160 | Human Anti-ENPP3 Recombinant Antibody (clone 3B2) | ELISA, FC | Human IgG1 |
VS-0723-WK17 | Human Anti-ENPP3 Recombinant Antibody (clone Xencor) | FC | Human IgG1 |
There are currently no Customer reviews or questions for ADC-021LZY. Click the button above to contact us or submit your feedback about this product.
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.